The contribution of the tumor stroma to the development of cancer has been described in recent years in both humans and mice, identifying it as an important new player in neoplastic initiation and progression.
The tumor stroma is made up of a variety of cellular components such as fibroblasts, myofibroblasts, blood vessels or cells of the immune system, as well as extracellular matrix proteins (ECM).
Most therapeutic approaches directly target tumor cells and, until recently, largely ignored the desmoplastic stromal reaction, which characterizes several types of solid cancer.
The identification of candidates jointly overexpressed in the tumor stroma and involved in immunosuppression could therefore provide new therapeutic targets.
StromaCare is dedicated to the development of innovative oncology drugs, based on modulation of stromal components, for the treatment of solid tumors.
StromaCare will focus on the development of these innovative compounds from translational research to proof of concept in humans, which represents its specific know-how and area of expertise.
StromaCare will direct its programs to the most attractive and value-creating point for potential partners.